Literature DB >> 12694316

Morphology of the heart and arteries in renal failure.

Karin Tyralla1, Kerstin Amann.   

Abstract

In patients with renal failure, cardiovascular complications are a major clinical problem; cardiac death is the main cause of death in these patients. Cardiac risk is increased by a factor of 20 in uremic patients, compared with matched segments of the general population. It has been known for a long time that atherosclerosis, particularly plaque in the epicardiac coronary conduit arteries, are more frequent in patients with chronic renal failure. Recently, however, clinical studies showed that myocardial infarction is responsible for only 30% to 50% of all cardiac deaths. In contrast, 30% to 40% of patients with renal failure and ischemic heart disease show patent coronary arteries on coronary angiogram. Thus, it is very likely that in uremic patients myocardial ischemia tolerance is markedly reduced even in the absence of classical atherosclerosis (i.e., relevant stenosis of coronary arteries). This finding in uremic patients can be at least partially explained by structural and metabolic abnormalities of the myocardium, and in part by alterations of the extracardiac vasculature. The present paper focuses on structural changes of the heart and the vasculature, in particular on atherosclerosis of cardiac and extracardiac arteries, and its potential repercussions for cardiovascular function. In 1827 Richard Bright already pointed to the common presence of left ventricular hypertrophy (LVH) and thickening of the aorta in patients with end-stage renal failure (ESRF). At present, cardiovascular complications account for 45% of all deaths in uremic patients [1]. The recent report of Herzog, Ma, and Colins [2] documented a 59.3% 1-year mortality rate in dialyzed patients who survived myocardial infarction (i.e., mortality was significantly higher than in the general population). It is widely acknowledged that several specific structural and nonstructural alterations of the heart and the extracardiac vasculature are present in patients with renal failure, which presumably contribute to the markedly increased cardiovascular risk in these patients [3].

Entities:  

Mesh:

Year:  2003        PMID: 12694316     DOI: 10.1046/j.1523-1755.63.s84.1.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  20 in total

Review 1.  Targeted metabolic imaging to improve the management of heart disease.

Authors:  Moritz Osterholt; Shiraj Sen; Vasken Dilsizian; Heinrich Taegtmeyer
Journal:  JACC Cardiovasc Imaging       Date:  2012-02

2.  Nonparallel Progression of Left Ventricular Structure and Function in Long-Term Peritoneal Dialysis Patients.

Authors:  Qiuhong Shi; Jing Zhu; Sheng Feng; Huaying Shen; Jianchang Chen; Kai Song
Journal:  Cardiorenal Med       Date:  2017-04-22       Impact factor: 2.041

3.  B-flow imaging estimation of carotid and femoral atherosclerotic plaques: vessel walls rheological damage or strong predictor of cardiovascular mortality in chronic dialysis patients.

Authors:  Petar Avramovski; Maja Avramovska; Aleksandar Sikole
Journal:  Int Urol Nephrol       Date:  2016-08-11       Impact factor: 2.370

4.  Monocyte angiotensin converting enzyme expression may be associated with atherosclerosis rather than arteriosclerosis in hemodialysis patients.

Authors:  Christof Ulrich; Eric Seibert; Gunnar H Heine; Danilo Fliser; Matthias Girndt
Journal:  Clin J Am Soc Nephrol       Date:  2010-12-02       Impact factor: 8.237

Review 5.  Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease.

Authors:  David Charytan
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-11       Impact factor: 2.894

6.  Pre-clinical myocardial metabolic alterations in chronic kidney disease.

Authors:  Jeffrey C Fink; Martin A Lodge; Mark F Smith; Anish Hinduja; Jeanine Brown; Mara Y Dinits-Pensy; Vasken Dilsizian
Journal:  Cardiology       Date:  2010-07-07       Impact factor: 1.869

Review 7.  αKlotho and Chronic Kidney Disease.

Authors:  J A Neyra; M C Hu
Journal:  Vitam Horm       Date:  2016-03-24       Impact factor: 3.421

8.  Cardiac hypertrophy in neonatal nephrectomized rats: the role of the sympathetic nervous system.

Authors:  Siddhartha S Ghosh; Richard J Krieg; Domenic A Sica; Ruipeng Wang; Itaf Fakhry; Todd Gehr
Journal:  Pediatr Nephrol       Date:  2008-09-17       Impact factor: 3.714

9.  Cardiac and kidney markers for cardiovascular prediction in individuals with chronic kidney disease: the Atherosclerosis Risk in Communities study.

Authors:  Kunihiro Matsushita; Yingying Sang; Shoshana H Ballew; Brad C Astor; Ron C Hoogeveen; Scott D Solomon; Christie M Ballantyne; Mark Woodward; Josef Coresh
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-05-29       Impact factor: 8.311

10.  Low-dose growth hormone is cardioprotective in uremia.

Authors:  Ralph Rabkin; Ibrahim Awwad; Yu Chen; Euan A Ashley; Difei Sun; Sumita Sood; William Clusin; Paul Heidenreich; Grzegorz Piecha; Marie-Luise Gross
Journal:  J Am Soc Nephrol       Date:  2008-07-23       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.